Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC)

European Journal of Epidemiology

Volumn 29, Issue 4, 2014, Pages 261-275

  Aleksandrova, Krasimira ^a   Jenab, Mazda ^b   Bueno de Mesquita, H Bas ^c,d   Fedirko, Veronika ^b,e,f   Kaaks, Rudolf ^g   Lukanova, Annekatrin ^g,h   Van Duijnhoven, Fränzel J B ^c,i   Jansen, Eugene ^c   Rinaldi, Sabina ^b   Romieu, Isabelle ^b   Ferrari, Pietro ^b   Murphy, Neil ^j   Gunter, Marc J ^j   Riboli, Elio ^j   Westhpal, Sabine ^k   Overvad, Kim ^l   Tjønneland, Anne ^m   Halkjær, Jytte ^m   Boutron Ruault, Marie Christine ^n,o   Dossus, Laure ^n,o   Racine, Antoine ^n,o   Trichopoulou, Antonia ^p,q   Bamia, Christina ^q   Orfanos, Philippos ^q   Agnoli, Claudia ^r   Palli, Domenico ^s   Panico, Salvatore ^t   Tumino, Rosario ^u   Vineis, Paolo ^j,v   Peeters, Petra H ^d,j   Duell, Eric J ^w   Molina Montes, Esther ^x,y,z   Quirós, J Ramón ^aa   Dorronsoro, Miren ^ab   Chirlaque, Maria Dolores ^y,ac   Barricarte, Aurelio ^ad   Ljuslinder, Ingrid ^ae   Palmqvist, Richard ^h   Travis, Ruth C ^af   Khaw, Kay Tee ^ag   Wareham, Nicholas ^ag   Pischon, Tobias ^ah   Boeing, Heiner ^a   more..

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e EMORY UNIVERSITY   (United States)

^f EMORY UNIVERSITY   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UMEÅ UNIVERSITY   (Sweden)

ⁱ WAGENINGEN UNIVERSITY   (Netherlands)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

^l AARHUS UNIVERSITY   (Denmark)

^m DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁿ CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^o IGR   (France)

^p HELLENIC HEALTH FOUNDATION   (Greece)

^q UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^r NATIONAL CANCER INSTITUTE   (Italy)

^s CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^t UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^u CIVILE M P AREZZO HOSPITAL   (Italy)

^v HuGeF Foundation   (Italy)

^w CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^x ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^y CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^z Granada Health Research Institute ibs GRANADA   (Spain)

^aa PUBLIC HEALTH DIRECTORATE   (Spain)

^ab Epidemiology and Health Information   (Spain)

^ac Murcia Regional Health Authority   (Spain)

^ad INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^ae UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^af UNIVERSITY OF OXFORD   (United Kingdom)

^ag UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ah MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

more..

Author keywords

Biomarker patterns; Colorectal cancer; European Prospective Investigation into Cancer and Nutrition (EPIC); Inflammatory and metabolic pathways; Principal component analysis

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LEPTIN RECEPTOR; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TRIACYLGLYCEROL; ADIPOCYTOKINE; TUMOR MARKER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECTUM CANCER; SEDENTARY LIFESTYLE; SEX DIFFERENCE; WAIST CIRCUMFERENCE; BLOOD; COLORECTAL TUMOR; EUROPE; INCIDENCE; INFLAMMATION; METABOLISM; MIDDLE AGED; PROGNOSIS; RISK FACTOR; SOCIOECONOMICS; STATISTICAL MODEL;

ADIPOKINES; AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; INFLAMMATION; LOGISTIC MODELS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; TRIGLYCERIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84903769474     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-014-9901-8     Document Type: Article

References (64)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. doi:10.1002/ijc.25516.
2. Aleksandrova K, Nimptsch K, Pischon T. Influence of obesity and related metabolic alterations on colorectal cancer risk. Curr Nutr Rep. 2013;2(1):1-9. doi:10.1007/s13668-012-0036-9.
3. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. Biochim Biophys Acta. 2013;1831(10):1499-508. doi:10.1016/j.bbalip.2013.02.008.
4. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933-47. doi:10.1136/gutjnl-2013-304701.
5. Hull M, Lagergren J. Obesity and colorectal cancer. Gut. 2013;.doi:10.1136/gutjnl-2013-304988.
6. Jenab M, Riboli E, Cleveland RJ, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121(2):368-76. doi:10.1002/ijc.22697. (Pubitemid 46917707)
7. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center-based Prospective Study Group. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer. 2007;120(9):2007-12. doi:10.1002/ijc.22556. (Pubitemid 46418381)
8. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96(7):546-53. (Pubitemid 38559579)
9. Rinaldi S, Rohrmann S, Jenab M, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3108-15. doi:10.1158/1055-9965.EPI-08-0495.
10. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(5):412-8. (Pubitemid 36578478)
11. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2010;172(4):407-18. doi:10.1093/aje/kwq135.
12. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123(5):1133-40. doi:10.1002/ijc.23606.
13. Leufkens AM, van Duijnhoven FJ, Woudt SH, et al. Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol. 2012;175(7):653-63. doi:10.1093/aje/kwr418.
14. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation intoCancer and Nutrition. Gut. 2011;60(8):1094-102. doi:10.1136/gut.2010.225011.
15. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 2010;55(25):2846-54. doi:10.1016/j.jacc.2009.12.069.
16. Lavigne PM, Jafri H, Karas R. High-density lipoprotein cholesterol and cancer incidence: data from the Framingham Heart Study. J Am Coll Cardiol. 2012;59(13s1):E1764. doi:10.1016/S0735-1097(12)61765-3.
17. Trayhurn P, Wood IS. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans. 2005;33(Pt 5):1078-81. doi:10.1042/BST20051078. (Pubitemid 41659117)
18. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005;64(2):163-9. (Pubitemid 40813538)
19. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547-94. doi:10.1210/er.2011-1015.
20. Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216(1):T1-15. doi:10.1530/JOE-12-0498.
21. AleksandrovaK, Boeing H, JenabM, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res. 2012;72(20):5328-37. doi:10.1158/0008-5472.CAN-12-0465.
22. Xu XT, Xu Q, Tong JL, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011;12(4):234-44. doi:10.1111/j.1751-2980.2011.00504.x.
23. Perrier S, Jarde T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem. 2012;19(32):5501-12.
24. Aleksandrova K, Boeing H, Jenab M, et al. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis. 2012;33(6):1211-8. doi:10.1093/carcin/bgs133.
25. Song M, Zhang X, Wu K, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res. 2013;6(9):875-85. doi:10.1158/1940-6207.CAPR-13-0169.
26. Neumeier M, Weigert J, Schaffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79(4):803-8. doi:10.1189/jlb.0905521. (Pubitemid 44835612)
27. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer. 2010;126(7):1702-15. doi:10.1002/ijc. 24927.
28. Chi F, Wu R, Zeng YC, Xing R, Liu Y. Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic reviewandmeta-analysis.Mol Biol Rep. 2013;40(5):3583-90. doi:10.1007/s11033-012- 2432-z.
29. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92(19):1592-600.
30. Mathews JD, Buckley JD, Gledhill VX. Pattern recognition in medicine - a place for the use of principal component analysis and factor analysis. Aust N Z J Med. 1974;4(5):509-15.
31. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. Curr Opin Lipidol. 2002;13(1):3-9. (Pubitemid 34174623)
32. Jolliffe I. Principal component analysis. New York: Springer; 1986.
33. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb. 1994;14(12):1940-5.
34. Dossus L, Lukanova A, Rinaldi S, et al. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis. Am J Epidemiol. 2013;177(8):787-99. doi:10.1093/aje/kws309.
35. Bingham S, Riboli E. Diet and cancer-the European Prospective Investigation into Cancer and Nutrition. Nat Rev Cancer. 2004;4(3):206-15. doi:10.1038/nrc1298nrc1298. (Pubitemid 38337500)
36. Slimani N, Deharveng G, Unwin I, et al. The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr. 2007;61(9):1037-56. doi:10.1038/sj.ejcn.1602679. (Pubitemid 47386588)
37. Kaaks R, Riboli E. Validation and calibration of dietary intake measurements in the EPIC project: methodological considerations. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol. 1997;26(Suppl 1):S15-25. (Pubitemid 27129686)
38. Haftenberger M, Lahmann PH, Panico S, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2002;5(6B):1147-62. (Pubitemid 36313610)
39. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393bmj.b2393.
40. Yuan Y. Multiple imputation using SAS software. J Stat Softw. 2011;45(6):1-25.
41. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113-24. doi:10.1079/PHN2002394S1368980002001350. (Pubitemid 36313608)
42. World Cancer Research Fund/American Institute for Cancer Research. Food nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
43. Rohrmann S, Linseisen J, Becker S, et al. Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2174-82. doi:10.1158/1055-9965. EPI-11-0179.
44. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res. 2011;4(11):1873-83. doi:10.1158/1940-6207. CAPR-11-0218.
45. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205-13. (Pubitemid 20126858)
46. Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett. 2003; 545(2-3):103-4. (Pubitemid 36694683)
47. Altinova AE, Toruner F, Bukan N, et al. Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr J. 2007;54(2):221-6. (Pubitemid 46798643)
48. Van Linthout S, Foryst-Ludwig A, Spillmann F, et al. Impact ofHDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis. 2010;210(2):438-44. doi:10.1016/j.atherosclerosis.2010.01.001.
49. Kangas-Kontio T, Huotari A, Ruotsalainen H, et al. Genetic and environmental determinants of total and high-molecular weight adiponectin in families with low HDL-cholesterol and early onset coronary heart disease. Atherosclerosis. 2010;210(2):479-85. doi:10.1016/j.atherosclerosis.2009.12.022.
50. Belalcazar LM, Lang W, Haffner SM, et al. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res. 2012;53(12):2726-33. doi:10.1194/jlr.M030213.
51. An W, Bai Y, Deng SX, et al. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21(2):126-33. doi:10.1097/CEJ.0b013e32834c9b55.
52. Moon HS, Liu X, Nagel JM, et al. Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013;62(4):561-70. doi:10.1136/gutjnl-2012-302092.
53. Per M. Oxidative stress in the pathogenesis of colorectal cancer: cause or consequence? Biomed Res Int. 2013;2013:9. doi:10.1155/2013/725710.
54. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biol Med. 2010;49(11):1603-16. doi:10.1016/j.freeradbiomed.2010.09.006.
55. Perse M. Oxidative stress in the pathogenesis of colorectal cancer: cause or consequence? Biomed Res Int. 2013;2013:725710. doi:10.1155/2013/725710.
56. Inokuma T, Haraguchi M, Fujita F, Tajima Y, Kanematsu T. Oxidative stress and tumor progression in colorectal cancer. Hepatogastroenterology. 2009;56(90):343-7.
57. Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, MantzorosCS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes. 2002;51(7):2105-12. (Pubitemid 34729014)
58. Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res. 2003;11(6):760-8. doi:10.1038/oby.2003.106. (Pubitemid 41151602)
59. Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol Disord: Drug Targets. 2011;10(8):921-7.
60. Kraegen EW, Cooney GJ, Ye J, Thompson AL. Triglycerides, fatty acids and insulin resistance-hyperinsulinemia. Exp Clin Endocrinol Diabetes. 2001;109(4):S516-26. (Pubitemid 32577694)
61. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36(3):232-40. doi:10.1016/j.arcmed.2005.01.005. (Pubitemid 40755136)
62. Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. Type II diabetes mellitus and cardiovascular risk factors: current therapeutic approaches. Exp Clin Cardiol. 2007;12(1):17-28. (Pubitemid 46566811)
63. Tsushima M, Nomura AM, Lee J, Stemmermann GN. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci. 2005;50(3):499-505. (Pubitemid 40543738)
64. Lee SA, Kallianpur A, Xiang YB, et al. Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2464-70. doi:10.1158/1055-9965.EPI-07-0374. (Pubitemid 351196382)